Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Herpes simplex virus vaccines.

D I Bernstein1, L R Stanberry

  • 1Division of Infectious Diseases, Children's Hospital Medical Center, Cincinnati, OH 45229, USA. dib@chmcc.org

Vaccine
|April 9, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts from the North American Rhinology & Allergy Conference, February 3, 2011, Puerto Rico.

American journal of rhinology & allergy·2017
Same author

Duration of day care attendance during infancy predicts asthma at the age of seven: the Cincinnati Childhood Allergy and Air Pollution Study.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2014
Same author

N-acetyltransferase 1 polymorphism increases cotinine levels in Caucasian children exposed to secondhand smoke: the CCAAPS birth cohort.

The pharmacogenomics journal·2014
Same author

A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2014
Same author

Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure.

Allergy·2014
Same author

Vaccines for cytomegalovirus.

Infectious disorders drug targets·2012
Same journal

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.

Vaccine·2026
Same journal

In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.

Vaccine·2026
Same journal

Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults.

Vaccine·2026
Same journal

Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls.

Vaccine·2026
Same journal

Public health benefits of maternal influenza vaccination among pregnant women and infants <6 months in the United States, 2011-2020.

Vaccine·2026
Same journal

Effectiveness and acceptability of an opt-out nudge to promote influenza vaccination among medical residents: A randomized controlled trial.

Vaccine·2026
See all related articles

Developing effective herpes simplex virus (HSV) vaccines requires understanding infection's unique lifecycle. This review explores prophylactic and therapeutic vaccine strategies, including novel DNA and replication-impaired virus approaches, to combat HSV disease.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Herpes simplex virus (HSV) infections cause primary, latent, and recurrent diseases.
  • Standard vaccine goals differ due to HSV's complex infection cycle.

Purpose of the Study:

  • To review prophylactic and therapeutic HSV vaccine objectives.
  • To correlate vaccine goals with HSV infection immunobiology.
  • To describe current and emerging HSV vaccine strategies.

Main Methods:

  • Review of existing literature on HSV vaccines.
  • Analysis of vaccine strategies in relation to HSV immunobiology.
  • Discussion of modern vaccine development methodologies.

Main Results:

Related Experiment Videos

  • Prophylactic and therapeutic vaccine goals for HSV are distinct.
  • Subunit glycoprotein vaccines are in late-stage evaluation.
  • Early-phase trials assess DNA-based and replication-impaired virus vaccines.

Conclusions:

  • Optimal HSV vaccine development may require identifying key antigens and routes for genital tract immunity.
  • Novel vaccine approaches are being explored.
  • Further research into HSV immunobiology is crucial for a definitive vaccine.